Trial · NCT06396039
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Annualized relapse rate (ARR) over 36 months | Up to 3 years | |
| Secondary | Annualized relapse rate (ARR) over 12 months and 24 months | Up to 2 years | |
| Secondary | The cumulative number of new or enlarging hyperintense T2-weighted brain MRI lesions at Months 12, 24, and 36 | Up to 3 years | |
| Secondary | The cumulative number of GdE brain MRI lesions at Months 12, 24, and 36 | Up to 3 years | |
| Secondary | Proportion of participants who are new or enlarging hyperintense T2 lesion free at Months 12, 24, and 36 | Up to 3 years | |
| Secondary | Proportion of participants who are GdE lesion-free at Months 12, 24, and 36 | Up to 3 years | |
| Secondary | Proportion of participants with adverse events (AEs) | Up to 40 months | |
| Secondary | Proportion of participants with serious adverse events (SAEs) | Up to 40 months | |
| Secondary | Proportion of participants with AEs leading to discontinuation of study treatment | Up to 3 years | |
| Secondary | Proportion of participants with laboratory abnormalities | Up to 40 months | |
| Secondary | Proportion of participants with vital sign abnormalities | Up to 40 months | |
| Secondary | Proportion of participants with electrocardiogram (ECG) abnormalities | Up to 40 months | |
| Secondary | Proportion of participants with physical examination abnormalities | Up to 40 months | |
| Secondary | Proportion of participants with serious or opportunistic infections | Up to 40 months | |
| Secondary | Proportion of participants with malignancy | Up to 40 months | |
| Secondary | Proportion of participants with bradycardia and heart condition abnormalities | Up to 40 months | |
| Secondary | Proportion of participants with pulmonary toxicity | Up to 40 months | |
| Secondary | Proportion of participants with macular edema | Up to 40 months | |
| Secondary | Proportion of participants with hepatotoxicity | Up to 40 months | |
| Secondary | Proportion of participants with posterior reversible encephalopathy syndrome | Up to 40 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06396039/registered